Convection-Enhanced Delivery

Overview

Journal Neurotherapeutics

Specialty Neurology

Date 2017 Mar 17

PMID 28299724

Citations 118

Authors

A M Mehta

A M Sonabend

J N Bruce

Affiliations

Soon will be listed here.

Abstract

Convection-enhanced delivery (CED) is a promising technique that generates a pressure gradient at the tip of an infusion catheter to deliver therapeutics directly through the interstitial spaces of the central nervous system. It addresses and offers solutions to many limitations of conventional techniques, allowing for delivery past the blood-brain barrier in a targeted and safe manner that can achieve therapeutic drug concentrations. CED is a broadly applicable technique that can be used to deliver a variety of therapeutic compounds for a diversity of diseases, including malignant gliomas, Parkinson's disease, and Alzheimer's disease. While a number of technological advances have been made since its development in the early 1990s, clinical trials with CED have been largely unsuccessful, and have illuminated a number of parameters that still need to be addressed for successful clinical application. This review addresses the physical principles behind CED, limitations in the technique, as well as means to overcome these limitations, clinical trials that have been performed, and future developments.

Citing Articles

Advances in the Repurposing and Blood-Brain Barrier Penetrance of Drugs in Pediatric Brain Tumors.

Rechberger J, Toll S, Biswas S, You H, Chow W, Kendall N Cancers (Basel). 2025; 17(3).

PMID: 39941807 PMC: 11816256. DOI: 10.3390/cancers17030439.

Utilization of nanotechnology to surmount the blood-brain barrier in disorders of the central nervous system.

Luo Q, Yang J, Yang M, Wang Y, Liu Y, Liu J Mater Today Bio. 2025; 31:101457.

PMID: 39896289 PMC: 11786670. DOI: 10.1016/j.mtbio.2025.101457.

Therapeutic manipulation and bypass of the blood-brain barrier: powerful tools in glioma treatment.

Giantini-Larsen A, Pandey A, Garton A, Rampichini M, Winston G, Goldberg J Neurooncol Adv. 2025; 7(1):vdae201.

PMID: 39877748 PMC: 11773386. DOI: 10.1093/noajnl/vdae201.

VRAC channel inhibition as a novel strategy for the treatment of ischemia-reperfusion injury.

Gao Y, Li L, Zhang Y, Chu Y, Han G Front Cell Dev Biol. 2025; 12:1524723.

PMID: 39763586 PMC: 11701159. DOI: 10.3389/fcell.2024.1524723.

pH-Responsive Polyethylene Glycol Engagers for Enhanced Brain Delivery of PEGylated Nanomedicine to Treat Glioblastoma.

Meng J, Dong Z, Chen Y, Lin M, Liu Y, Roffler S ACS Nano. 2025; 19(1):307-321.

PMID: 39749925 PMC: 11752499. DOI: 10.1021/acsnano.4c05906.

References

Liu H, Jacobs B, Liu J, Prayson R, Estes M, Barnett G . Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: non-neoplastic glia and low-grade astrocytoma differ from malignant glioma. Cancer Immunol Immunother. 2000; 49(6):319-24. PMC: 11036967. DOI: 10.1007/s002620000110. View

Yun J, Rothrock R, Canoll P, Bruce J . Convection-enhanced delivery for targeted delivery of antiglioma agents: the translational experience. J Drug Deliv. 2013; 2013:107573. PMC: 3586495. DOI: 10.1155/2013/107573. View

LIEBERMAN D, Laske D, Morrison P, Bankiewicz K, Oldfield E . Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg. 1995; 82(6):1021-9. DOI: 10.3171/jns.1995.82.6.1021. View

Frazier J, Lee J, Thomale U, Noggle J, Cohen K, Jallo G . Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies. J Neurosurg Pediatr. 2009; 3(4):259-69. DOI: 10.3171/2008.11.PEDS08281. View

Lopez K, Tannenbaum A, Assanah M, Linskey K, Yun J, Kangarlu A . Convection-enhanced delivery of topotecan into a PDGF-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells and recruited glial progenitors. Cancer Res. 2011; 71(11):3963-71. PMC: 3113406. DOI: 10.1158/0008-5472.CAN-10-0906. View

Johnson V, Wrobel C, Wilson D, Zovickian J, Greenfield L, Oldfield E . Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J Neurosurg. 1989; 70(2):240-8. DOI: 10.3171/jns.1989.70.2.0240. View

Prior R, Reifenberger G, WECHSLER W . Transferrin receptor expression in tumours of the human nervous system: relation to tumour type, grading and tumour growth fraction. Virchows Arch A Pathol Anat Histopathol. 1990; 416(6):491-6. DOI: 10.1007/BF01600299. View

Morrison P, Laske D, Bobo H, Oldfield E, Dedrick R . High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol. 1994; 266(1 Pt 2):R292-305. DOI: 10.1152/ajpregu.1994.266.1.R292. View

Sandberg D, Edgar M, Souweidane M . Convection-enhanced delivery into the rat brainstem. J Neurosurg. 2002; 96(5):885-91. DOI: 10.3171/jns.2002.96.5.0885. View

10.

Pommier Y . Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006; 6(10):789-802. DOI: 10.1038/nrc1977. View

11.

Casanova F, Carney P, Sarntinoranont M . Effect of needle insertion speed on tissue injury, stress, and backflow distribution for convection-enhanced delivery in the rat brain. PLoS One. 2014; 9(4):e94919. PMC: 4002424. DOI: 10.1371/journal.pone.0094919. View

12.

Raghavan R, Brady M, Rodriguez-Ponce M, Hartlep A, Pedain C, Sampson J . Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus. 2006; 20(4):E12. DOI: 10.3171/foc.2006.20.4.7. View

13.

Healy A, Vogelbaum M . Convection-enhanced drug delivery for gliomas. Surg Neurol Int. 2015; 6(Suppl 1):S59-67. PMC: 4338487. DOI: 10.4103/2152-7806.151337. View

14.

Sillay K, McClatchy S, Shepherd B, Venable G, Fuehrer T . Image-guided convection-enhanced delivery into agarose gel models of the brain. J Vis Exp. 2014; (87). PMC: 4186391. DOI: 10.3791/51466. View

15.

Andtbacka R, Kaufman H, Collichio F, Amatruda T, Senzer N, Chesney J . Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25):2780-8. DOI: 10.1200/JCO.2014.58.3377. View

16.

Fiandaca M, Forsayeth J, Dickinson P, Bankiewicz K . Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics. 2008; 5(1):123-7. PMC: 2719019. DOI: 10.1016/j.nurt.2007.10.064. View

17.

Heiss J, Walbridge S, Morrison P, Hampton R, Sato S, Vortmeyer A . Local distribution and toxicity of prolonged hippocampal infusion of muscimol. J Neurosurg. 2005; 103(6):1035-45. PMC: 4294277. DOI: 10.3171/jns.2005.103.6.1035. View

18.

Lesniak M, Brem H . Targeted therapy for brain tumours. Nat Rev Drug Discov. 2004; 3(6):499-508. DOI: 10.1038/nrd1414. View

19.

Chen P, Ozawa T, Drummond D, Kalra A, Fitzgerald J, Kirpotin D . Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro Oncol. 2012; 15(2):189-97. PMC: 3548589. DOI: 10.1093/neuonc/nos305. View

20.

Gill S, Patel N, Hotton G, OSullivan K, McCarter R, Bunnage M . Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003; 9(5):589-95. DOI: 10.1038/nm850. View